AI Companies That Invest in Better Data Pipelines are Winning Faster Regulatory Approvals — Here’s Why
Medical AI developers who prioritize data early will be the ones crossing the regulatory finish…
AI Companies That Invest in Better Data Pipelines are Winning Faster Regulatory Approvals — Here’s Why
Medical AI developers who prioritize data early will be the ones crossing the regulatory finish line faster and more reliably. The post AI Companies That Invest in Better Data Pipelines are Winning Faster Regulatory Approvals — Here’s Why appeared first on MedCity News.
What Excites Zimmer Biomet’s CIO About MedTech Right Now?
Shaun Braun, Zimmer Biomet’s chief information and technology officer, said today’s biggest medtech innovation is the field’s focus on connection and interoperability. By integrating data, AI and robotics into a single ecosystem, the company is seeking to deliver more personalized care and improve surgical outcomes. The post What Excites Zimmer Biomet’s CIO About MedTech Right…
Represión de Trump empuja a inmigrantes víctimas de violencia doméstica a las sombras
Línea de ayuda nacional para casos de violencia doméstica: Las personas que han sufrido abuso doméstico pueden recibir ayuda confidencial en thehotline.org o llamando al 800-799-7233. La inmigrante originaria de India le creyó a su esposo cuando le dijo por teléfono que la mataría, si todavía estaba en su casa de Georgia para cuando él…
Conflicting Advice on Covid Shots Likely To Ding Already Low Vaccine Rates, Experts Warn
More than three-quarters of American adults didn’t get a covid shot last season, a figure that health care experts warn could rise this year amid new U.S. government recommendations. The covid vaccine was initially popular. About 75% of Americans had received at least one dose of the first versions of the vaccine by early 2022,…
Listen: New Federal Guidelines Could Weaken Consumer Protections Against Medical Debt
LISTEN: Bad credit can keep you from getting a job, a car loan, or an apartment to rent. For many Americans, health care debt is to blame. KFF Health News senior correspondent Noam N. Levey appeared on WAMU’s “Health Hub” on Nov. 12 to explain why new federal guidelines on health care debt and credit…
KFF Health Tracking Poll: Prescription Drug Costs, Views on Trump Administration Actions, and GLP-1 Use
About one in eight adults say that they are currently taking a GLP-1 drug either to lose weight or treat a chronic condition, an increase from 18 months ago, though the high costs of the medications remain a concern. Few adults think it is likely their prescription costs will go down as a result of…
Poll: 1 in 8 Adults Say They Are Currently Taking a GLP-1 Drug for Weight Loss, Diabetes or Another Condition, Even as Half Say the Drugs Are Difficult to Afford
About one in eight adults (12%) say that they are currently taking a GLP-1 drug such as Ozempic or Wegovy either to lose weight or treat a chronic condition, an increase from 18 months ago, though the high costs of the medications remain a concern, a new KFF Health Tracking Poll finds.
A Failure to Rescue: How Predictive Modeling Can Rewrite the Story of Congenital Syphilis
By KAYLA KELLY Every semester I have the privilege of guiding nursing students through their maternal and pediatric clinicals. At the beginning of the semester, their enthusiasm is contagious. They share stories about witnessing their first delivery, helping a new mother with breastfeeding, and practicing developmental assessments on pediatric patients. As the semester progresses, I…
MFN comes to Medicaid under the GENEROUS program
Last week, CMS announced the GENEROUS (GENErating cost Reductions fOr U.S. Medicaid) Model. The program basically is a ‘most favored nation’ style reference pricing based on net prices from developed countries. The program builds on the Medicaid Drug Rebate Program (MDRP). Specific details specified on the CMS website include: Participating manufacturers whose applications are accepted…
Despite Competition, All Big 4 Ambient Company CEOs Believe They Will Succeed
The CEOs of Nabla, Suki, Ambience Healthcare and Abridge separately spoke with MedCity News about why their products have staying power despite imminent competition from Epic. The post Despite Competition, All Big 4 Ambient Company CEOs Believe They Will Succeed appeared first on MedCity News.
